Paysign(US:PAYS)2025-11-13 12:17Revenue Growth - Total revenues for the three months ended September 30, 2025, increased by $6,340,047, or 41.6%, compared to the same period in 2024, reaching $21,596,478[108]. - For the nine months ended September 30, 2025, total revenues increased by $16,494,876, or 38.6%, compared to the same period in the prior year, driven by a 191.3% increase in pharma revenue[118]. Profitability - Gross profit for the three months ended September 30, 2025, increased by $3,677,075, or 43.4%, resulting in a gross margin of 56.3%[108][111]. - Net income for the three months ended September 30, 2025, was $2,215,135, reflecting a 54.2% increase compared to $1,436,837 in 2024[108]. - Gross profit for the nine months ended September 30, 2025 increased by $12,598,054, or 54.8%, resulting from the launch of additional pharma patient affordability programs[121]. - The net income for the nine months ended September 30, 2025 was $6,188,996, an increase of $3,745,961, or 153.3%, compared to the net income of $2,443,035 for the same period in 2024[127]. Operating Expenses - Operating expenses increased by $2,784,973, or 35.8%, totaling $10,568,438 for the same period[108]. - Selling, general and administrative expenses for the nine months ended September 30, 2025 increased by $5,826,732, or 32.1%, primarily due to increased compensation and benefits[122]. Claims Processing - The number of claims processed increased over 60% in Q3 2025 compared to the same period in the prior year[109]. - The number of claims processed increased over 90% for the nine months ending September 30, 2025 compared to the same period in the prior year[119]. Cash Flow and Investments - Net cash provided by operating activities for the nine months ended September 30, 2025, was $4,360,171, a decrease of 49.5% from $8,633,922 in 2024[134]. - Cash used in investing activities increased to $8,436,339 for the nine months ended September 30, 2025, compared to $7,087,867 in 2024, primarily due to investments in software licenses and the Gamma acquisition[137]. - The company repurchased 100,000 shares of common stock at a weighted average price of $3.76 per share during the nine months ended September 30, 2025[138]. Tax and Other Financial Metrics - The effective tax rate for the nine months ended September 30, 2025 was 17.9%, compared to 15.8% for the same period in 2024[126]. - Adjusted EBITDA for the nine months ended September 30, 2025, was $14,512,453, up from $6,756,410 in 2024, reflecting a growth of 114.5%[132]. - EBITDA margin for the three months ended September 30, 2025, improved to 17.5%, compared to 14.8% in the same period of 2024[133]. Future Outlook - The company plans to continue investing in technology improvements, sales and marketing, and regulatory compliance throughout 2025[107]. - The company expects available cash and forecasted revenues to sustain operations for the next twenty-four months[140].